Exenatide formulations show variable nausea rates: the twice-daily immediate-release preparation (Byetta) tends to produce higher rates of nausea (approximately 3050%), whilst the once-weekly extended-release formulation (Bydureon) demonstrates improved tolerability with nausea rates of approximately 1424%, according to their respective SmPCs
Struck E, Ashmore J, Wieland O
Vieillissement : Il est tabli que le vieillissement s'accompagne d'une chute rapide de nos niveaux de glutathion
Before starting retatrutide (within a trial setting), your clinician should: Conduct a thorough medical history review , including assessment of conditions that may be trial exclusion criteria or require particular caution for example, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
Subcutaneous injection means the peptide goes into the fat layer just beneath the skin, not into muscle